NCT02723578 2020-01-13
Pemetrexed and Erlotinib for Metastatic Colorectal Cancer
Yonsei University
Phase 2 Completed
Clinical Trials
9 trialsNCT00940316 2019-05-07
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Northwestern University
Phase 2 Completed
NCT00265824 2015-12-11
DREAM
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 3 Completed
NCT01229813 2015-04-13
ACT2
Lund University Hospital
Phase 3 Completed
NCT00642746 2014-09-26
Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00598156 2013-04-22
ACT
Lund University Hospital
Phase 3 Completed
NCT00118261 2012-09-03
Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00123851 2009-04-28
Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00116506 2007-12-21
Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed